Somatic alterations in the human cancer genome  by Weir, Barbara et al.
CANCER CELL : NOVEMBER 2004 · VOL. 6 · COPYRIGHT © 2004 CELL PRESS 433
Introduction
Cancer is caused by alterations in the control and activity of
genes that in turn regulate cell growth and differentiation, lead-
ing to abnormal cell proliferation. These “cancer-related genes”
fall into two major classes that have opposite effects on normal
cell proliferation and opposite modes of alteration in cancer
cells.Tumor suppressor genes normally repress cell growth and
are inactivated in cancer, while oncogenes, which normally
stimulate cell growth, become hyperactivated in cancer
(Weinberg, 1996).
Specific changes in the cancer genome sequence lead to
disregulation of cancer-related genes. Among these changes
are germline variations that lead to hereditary cancer predispo-
sitions, the acquisition of transforming DNA or RNA sequences
from cancer viruses, and somatic changes in the cancer
genome. Each of these mechanisms may lead to the activation
of oncogenes or the inactivation of tumor suppressor genes.
Epigenetic mechanisms, such as DNA methylation or histone
modification, have also been postulated to promote oncogene-
sis by modifying the activity of cancer-related genes, but the evi-
dence for this mechanism, although substantial, is less
definitive to date.
Among these mechanisms, somatic genomic alteration
appears to be the major causative factor in most human can-
cers. Early in the last century, Boveri first proposed that somatic
changes in chromosomes could lead to cancer (Knudson, 2000,
2002). The first physical reification of this concept was the
demonstration that chronic myelogenous leukemia (CML) is
consistently associated with a recurrent chromosomal translo-
cation, the Philadelphia chromosome, as shown by Nowell and
Hungerford in 1960 (Nowell and Hungerford, 1960).
Remarkably, research building on the discovery of the
Philadelphia chromosome, spanning the past four decades, has
led to the development of one of the first effective targeted ther-
apies for cancer: the use of the tyrosine kinase inhibitor imatinib
or Gleevec to treat CML.The major milestones in this work were
the findings that the Philadelphia chromosome represents a
translocation between chromosomes 9 and 22 (Rowley, 1973a,
1973b), that this translocation leads to a fusion between the Bcr
gene and the Abl tyrosine kinase gene (reviewed in Daley and
Ben-Neriah, 1991), that imatinib can block the growth of CML
cells in model systems by inhibiting Abl kinase activity (Druker
et al., 1996), and finally that imatinib treatment of CML leads to
remission in the overwhelming majority of patients (Druker et
al., 2001). The path from the Philadelphia chromosome to ima-
tinib treatment, as well as the similar path from the discovery of
the neu oncogene to the development of therapy with
trastuzumab or Herceptin (Akiyama et al., 1986; Bargmann et
al., 1986; Coussens et al., 1985; King et al., 1985; Slamon et al.,
2001), provides a new paradigm for cancer treatment by target-
ing the somatic molecular alterations that cause cancer.
A recent review has thoroughly summarized the range of
known genomic alterations leading to cancer gene activation
and inactivation (Futreal et al., 2004). This review will focus on
the opportunities for cancer gene discovery based on the recent
sequencing of the human genome and discuss some of the
recent findings based on whole-genome analysis.
Cancer gene discovery by genome-wide screens prior to
the completion of the human genome sequence
Before the recent determination of the complete human
genome sequence, a variety of systematic “genome-wide”
approaches led to the discovery of most of the important known
cancer genes. These include cancer cell cytogenetics, onco-
gene transfection, mapping of genes that cause familial cancer
syndromes, and genome-wide searches for allelic loss of het-
erozygosity and homozygous deletions.
The first evidence of cancer causation by genomic changes
was the discovery of chromosome translocations in cancer,
beginning with the Philadelphia chromosome that is pathogenic
for CML. Using the techniques of cytogenetics, most notably
chromosome banding, probably the first method for genome-
wide exploration of cancer and other diseases, numerous onco-
genes activated by chromosome translocation have been
identified, as described in recent reviews (Mitelman, 2000;
Mitelman et al., 1997; Rabbitts, 1994). Another early fruitful
approach for oncogene discovery in cancer was the identifica-
tion of genes isolated from cancer cells that could transform tis-
sue culture cells in vitro. While oncogene transformation assays
are not based on knowledge of the genome sequence, they 
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are nevertheless unbiased, genome-wide screens. These
approaches have led to the identification of many cellular onco-
genes, including the human homologs of myc, ras, abl, neu,
their relatives, and others. The identification of Her2-Neu or
ERBB2 (Bargmann et al., 1986) by this approach is particularly
important as it has helped lead to the development of the target-
ed breast cancer therapy trastuzumab (Herceptin) (Slamon et
al., 2001).While the pace of oncogene discovery using transfec-
tion approaches has slowed dramatically, it is unclear whether
new ways of library construction and gene delivery may be use-
ful for this purpose.
The discovery of tumor suppressor genes has been mainly
achieved by the study of familial cancer syndromes and by map-
ping of regions of cancer-specific allelic loss of heterozygosity.
Here, one of the key developments was the production of
genome maps, in particular by the use of restriction fragment
length polymorphisms (RFLPs), making it possible to map
genetic disorders systematically. This was first applied to a vari-
ety of X-linked disorders such as chronic granulomatous dis-
ease and Duchenne’s muscular dystrophy. In the cancer field,
the recognition of tumor suppressor genes underlying heredi-
tary disorders began with the cloning of the retinoblastoma
tumor suppressor gene, accomplished by a combination of
genetic linkage studies using RFLPs and mapping of homozy-
gous deletions (Cavenee et al., 1983; Friend et al., 1986).
Another example was the cloning of the adenomatosis polypo-
sis coli (APC) tumor suppressor gene through a combination of
linkage analysis, deletion mapping, and mutation discovery in
individuals with familial adenomatous polyposis, a disease
which often leads to colorectal cancer (reviewed in Fearnhead
et al., 2001).
The discovery of the first tumor suppressor gene, RB1
(Friend et al., 1986), confirmed the Knudson “two-hit” hypothe-
sis (Knudson, 1971), which states that tumor suppressor genes
are inactivated by a recessive mutation in one allele followed by
the loss of the other wild-type allele, a phenomenon termed loss
of heterozygosity (LOH). By using initially RFLPs, then
microsatellite markers, and then single-nucleotide polymor-
phisms, it has been possible to generate genome-wide maps of
cancer LOH. These LOH maps have proven critical in localizing
regions that are commonly deleted in cancer, such as chromo-
some 9p and chromosome 18q. These regions have subse-
quently been shown to harbor tumor suppressor genes,
p16INK4a on chromosome 9 (Kamb et al., 1994; Nobori et al.,
1994) and SMAD4/DPC4 on chromosome 18 (Hahn et al.,
1996). Comparative genomic hybridization studies have also
identified many common regions of loss in cancers, pointing to
potential tumor suppressor gene loci (reviewed in Knuutila et
al., 1999). Cytogenetic and LOH studies also identified a poten-
tial tumor suppressor gene locus at 10q23 in some cancers,
including prostate and glioblastoma (reviewed in Dahia, 2000).
Representational difference analysis (RDA) and deletion map-
ping identified a candidate tumor suppressor gene, PTEN, from
the areas of common deletion at this locus (reviewed in Dahia,
2000). RDA is a method that subtracts genomic representations
of tumor from normal DNA to identify regions of gene deletion
using multiple enrichment rounds of hybridization and PCR; the
inverse subtraction of normal from tumor DNA representations
is used to identify tumor viruses and high-level amplifications
(Lisitsyn et al., 1995).
The amplification of chromosomal regions is a frequent way
of increasing gene expression in cancer cells. Commonly ampli-
fied regions have been found in many cancer types through
cytogenetic methods such as comparative genomic hybridiza-
tion (reviewed in Knuutila et al., 1998). These regions often
point to the location of potential oncogenes.
Genomic instability is often a driving force behind changes
in the cancer genome. Mutations in nonhereditary polyposis
colon cancer as well as xeroderma pigmotensum, Fanconi ane-
mia, and ataxia telangiectasia, among others, lead to defects in
DNA repair (D’Andrea and Grompe, 2003; Hoeijmakers, 2001;
Lengauer et al., 1998). These in turn may cause mutations in
oncogenes or tumor suppressor genes; for example, cancer cell
lines with high rates of microsatellite instability have been found
to contain presumed inactivating mutations in the gene for TGF
β receptor type II (Markowitz et al., 1995). Whether similar
mechanisms underlie the development of mutations in sporadic
cancers remains unclear.
Cancer molecular pathogenesis after the human genome
sequence
The draft sequencing of the complete human genome (Lander
et al., 2001; Venter et al., 2001) now makes it possible to query
the cancer genome systematically in ways that were hitherto
impossible. The two major advances are the opportunity to look
throughout the genome at the full range of copy number and
allelic changes in cancer compared to the germline and the abil-
ity to survey particular gene families (e.g., kinases, phos-
phatases, G protein-coupled receptors, etc.) in a complete
manner for somatic mutations.
Systematic copy number analysis
Oncogene activation in cancer is often a consequence of chro-
mosomal copy number amplification, while tumor suppressor
gene inactivation is often caused by either hemizygous deletion
associated with mutation or by homozygous deletion. Thus, the
identification of copy number alterations is a powerful tool for
cancer gene discovery. With the mapping of the genome and
the identification of large numbers of expressed genes, it
became possible to explore the full range of genome copy num-
ber alterations by hybridization to arrays of bacterial artificial
chromosomes (BACs) or to cloned cDNAs (reviewed in
Albertson and Pinkel, 2003).
Higher-density tools for genome copy number analysis have
become available with the completion of the human genome
sequence. These include genome tiling BAC arrays (Ishkanian
et al., 2004), oligonucleotide arrays for CGH (Brennan et al.,
2004; Lucito et al., 2003), copy number analysis using SNP
microarrays (Bignell et al., 2004; Zhao et al., 2004), and digital
karyotyping (Wang et al., 2002).The resulting quantitative mea-
surements of DNA copy number provide precise mapping infor-
mation for amplicons and regions harboring homozygous
deletions throughout the genome.
Digital karyotyping, a genomic version of the serial analysis
of gene expression (SAGE) technique, uses the quantification
of short, unique tags along the genome to assess copy number
changes through sequencing (Wang et al., 2002). Recently, a
new version of digital karyotyping has been developed using
tags released from type IIB restriction enzymes, which is
promising for the analysis of paraffin-embedded clinical sam-
ples (Tengs et al., 2004).
Finally, a new sequence-based method allows the simulta-
neous detection of complex structural changes including
translocations at the same time as copy number analysis, by
sequencing BAC ends and aligning them along the known
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genomic sequence (Volik et al., 2003). The applications of this
promising approach are yet to be developed.
Systematic LOH analysis
Traditionally, polymorphic markers, such as RFLPs and
microsatellites, have been used to detect LOH through allelo-
typing the DNA from a cancer sample and a corresponding nor-
mal sample (Vogelstein et al., 1989). However, these assays are
difficult to automate and are not readily scalable. Although unbi-
ased genome-wide analyses have also been performed, most
studies have used only a limited number of markers. The com-
pletion of the human genome has allowed for the identification
of millions of SNP loci, making them ideal markers for genetic
analysis. Due to their frequency in the genome and ease to
automate using an array platform (Wang et al., 1998), they pro-
vide an attractive method to analyze LOH at a genome-wide
level (Lindblad-Toh et al., 2000; Mei et al., 2000). LOH patterns
generated by SNP array have a high degree of concordance
with previous microsatellite analyses of the same cancer sam-
ples (Lindblad-Toh et al., 2000). In addition, shared regions of
LOH from SNP arrays are able to cluster lung cancer samples
into subtypes (Janne et al., 2004), and distinct patterns of LOH
are found to associate with clinical features in primary breast,
bladder, and prostate tumors (Hoque et al., 2003; Lieberfarb et
al., 2003; Wang et al., 2004b). The hybridization intensity of
DNA from tumor samples to high-density SNP arrays can also
be used to infer copy number with a high degree of accuracy
(Bignell et al., 2004; Zhao et al., 2004). Using SNP arrays, copy
number analysis can be performed in combination with LOH
analysis to distinguish copy number gains, copy neutral loss of
heterozygosity, and copy number losses, providing a compre-
hensive map of genetic alterations within a cancer cell (Zhao et
al., 2004).
Expression analysis and gene target discovery
Recent gene expression profiling revealed that lymphoblastic
leukemias with MLL translocation had a unique expression sig-
nature and can be separated from conventional acute lym-
phoblastic and acute myelogenous leukemias. Among the
features of the MLL group was high expression of the receptor
tyrosine kinase gene FLT3 (Armstrong et al., 2002).
Subsequent studies have shown that FLT3 is frequently mutat-
ed in MLL, and evidence suggests that the inhibitor PKC412 is
active against MLL cells in xenografts (Armstrong et al., 2003).
Expression analysis has also been combined with copy
number analyses, such as fluorescence in situ hybridization
(FISH), array CGH, and other methods, in an effort to elucidate
the critical target genes within DNA amplicons. Several array
CGH studies have shown a genome-wide correlation of gene
expression with copy number alterations and have proved use-
ful in individual amplicon refinement (Pollack et al., 2002; Wolf
et al., 2004). For example, through tissue microarray FISH and
RT-PCR, a minimally amplified region around ERBB2 was iden-
tified in a large number of breast tumors; in addition, gene
amplification was found to be correlated with increased gene
expression in a subset of those genes (Kauraniemi et al., 2003).
Cancer genome sequencing by gene family: kinases,
phosphatases, PI3-kinases
The completion of the human genome sequence allows for the
direct identification of mutations involved in cancer, by rese-
quencing DNA from tumor tissue. Mutations in cancer-causing
genes are increasingly being identified, and these searches can
be focused on specific protein families. In all cases, functional
analyses are needed to distinguish noncausative passenger
mutations from those with true roles in tumorigenesis. Several
stories are emerging from the identification of these mutations
and, in some cases, their correlation with clinical features. Such
studies have led to new insights into cancer pathogenesis with
immediate and long-term clinical implications.
By using denaturing capillary gel electrophoresis to detect
mutations, activating mutations in the BRAF kinase gene were
discovered in a variety of malignancies (Davies et al., 2002).
Notably, the BRAF mutations occur in over 60% of melanomas,
suggesting that BRAF could be a therapeutic target for the treat-
ment of melanoma and other cancers (Davies et al., 2002;
Tuveson et al., 2003). Activating BRAF mutations have also
been found in other cancers, including papillary thyroid cancers,
colorectal cancers, and primary lung adenocarcinomas
(Tuveson et al., 2003). BRAF mutations are generally nonover-
lapping with mutations in KRAS, a member of the same path-
way frequently activated in human cancers (Brose et al., 2002;
Naoki et al., 2002; Rajagopalan et al., 2002). This suggests that
only one mutational event in this pathway may be needed for
tumorigenesis.
Advances in sequencing technology now make it possible
to perform exon resequencing for gene families involved in cel-
lular signaling pathways, such as tyrosine kinases, tyrosine
phosphatases, and phosphatidylinositol 3-kinases (Bardelli et
al., 2003; Lynch et al., 2004; Paez et al., 2004; Samuels et al.,
2004; Stephens et al., 2004; Wang et al., 2004a). These studies
have identified cancer-specific somatic mutations in several
tyrosine kinase and tyrosine phosphatase genes as well as in
one PI3 kinase gene (PIK3CA), which encodes the p110α cat-
alytic subunit of phosphatidylinositol 3-kinase.
Somatic mutations within the PIK3CA gene were located in
regions where mutations are predicted to increase its catalytic
activity and were found in a significant fraction of colorectal can-
cers and glioblastomas (Samuels et al., 2004) as well as breast
carcinomas (Bachman et al., 2004). The region harboring
PIK3CA is often amplified in many different types of cancers
and is both amplified and overexpressed in cervical and ovarian
cancers, consistent with a likely role as an oncogene (Ma et al.,
2000; Shayesteh et al., 1999).
Systematic sequencing of protein kinase genes in colorec-
tal cancers led to the identification of somatic mutations in the
NTRK3, FES, KDR, EPHA3, NTRK2 MLK4, and GUCY2F
genes, with a high prevalence of mutations found in the kinase
domain (Bardelli et al., 2003). Followup studies of these kinase
genes in colorectal and other cancers will determine whether
they play a causative role in tumorigenesis.
In non-small cell lung carcinoma, the most common cause
of cancer death in the United States and worldwide, systematic
exon resequencing of tyrosine kinase genes identified muta-
tions within the epidermal growth factor receptor (EGFR) tyro-
sine kinase gene (Paez et al., 2004). The frequencies of these
mutations within lung adenocarcinomas vary between samples
from Japan (30%) and the United States (15%). The reason for
this difference between distinct populations is unknown but is
consistent with the concept that molecular mechanisms of
oncogenesis may vary among such groups.
The finding of mutations in EGFR in lung adenocarcinoma
is of significant clinical interest, because the compound gefitinib
(Iressa), an EGFR kinase inhibitor, has shown significant activi-
ty in the treatment of lung adenocarcinoma patients, most
notably in patients from Japan, nonsmokers, and women (Miller
et al., 2004). Three groups, using different approaches, found
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that mutations in the EGFR kinase domain in non-small cell car-
cinoma specimens correlated closely with patient responses to
gefitinib (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004).
Two studies approached EGFR mutation in a hypothesis-driven
manner (Pao et al., 2004; Lynch et al., 2004), while another
study came from a genome-scale effort to sequence all tyrosine
kinase genes in cancer, as described above (Paez et al., 2004).
Clinical testing for EGFR mutation in lung carcinoma is now
available and may aid in the selection of patients for therapy
with gefitinib and with related agents such as erlotinib (Tarceva),
for which clinical response is also related to EGFR mutation
(Pao et al., 2004).
Another recent study found kinase domain mutations of
ERBB2 in 4% of primary lung carcinomas and 10% of lung
adenocarcinomas (Stephens et al., 2004). The relationship
between these mutations and susceptibility to kinase inhibitors
has not yet been described.
Finally, predicted inactivating mutations within six protein
tyrosine phosphatases genes, PTPRF, PTPRG, PTPRT,
PTPN3, PTPN13, and PTPN14, have been identified by sys-
tematic exon resequencing of these genes from colorectal can-
cers (Wang et al., 2004a). Biochemical studies of the most
commonly altered gene, PTPRT, suggest that it is likely to func-
tion as a tumor suppressor gene (Wang et al., 2004a). In addi-
tion to colorectal cancer, some of these mutations have been
found in other cancer types, and these mutations cluster in evo-
lutionarily conserved domains, giving more evidence that they
play a functional role in tumorigenesis (Wang et al., 2004a).
In summary, the approach of systematic exon resequencing
has begun to identify a wide variety of somatic mutations in can-
cers, many of which have significant therapeutic implications. It
is likely that many more cancer-causing mutations will be identi-
fied via targeted genome resequencing, in addition to those
somatic alterations identified using complementary approaches
such as systematic copy number, LOH, and expression
analyses. As the power of sequencing technologies continues
to increase with the development of novel high-throughput
approaches (Brenner et al., 2000; Mitra et al., 2003; Shendure
et al., 2004), the scale of cancer genome sequencing should
increase proportionally. One can envision a future in which the
sequencing of cancer-specific mutations will take its place
alongside microscopic examination of cancer histology as the
mainstay of cancer diagnosis.
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